XML 23 R11.htm IDEA: XBRL DOCUMENT v3.7.0.1
Intangible Assets
6 Months Ended
Mar. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets Disclosure [Text Block]
Note 5 – Intangible Assets
 
Intangible assets at March 31, 2017 and September 30, 2016 consist of the following:
 
 
 
Useful
 
Gross
 
Accumulated
 
 
 
March 31, 2017
 
Life (years)
 
Amount
 
Amortization
 
Net
 
Acquired Customer Base
 
5 to 15
 
$
691,000
 
$
487,000
 
$
204,000
 
Know How
 
15
 
 
512,000
 
 
299,000
 
 
213,000
 
Trade Names
 
Indefinite
 
 
261,000
 
 
-
 
 
261,000
 
Patents
 
20
 
 
389,000
 
 
10,000
 
 
379,000
 
Biomedical Technologies
 
5
 
 
260,000
 
 
260,000
 
 
-
 
 
 
 
 
$
2,113,000
 
$
1,056,000
 
$
1,057,000
 
 
 
 
Useful
 
Gross
 
Accumulated
 
 
 
September 30, 2016
 
Life (years)
 
Amount
 
Amortization
 
Net
 
Acquired Customer Base
 
5 to 15
 
$
718,000
 
$
473,000
 
$
245,000
 
Know How
 
15
 
 
512,000
 
 
282,000
 
 
230,000
 
Trade Names
 
Indefinite
 
 
272,000
 
 
-
 
 
272,000
 
Patents
 
20
 
 
326,000
 
 
6,000
 
 
320,000
 
Biomedical Technologies
 
5
 
 
260,000
 
 
260,000
 
 
-
 
 
 
 
 
$
2,088,000
 
$
1,021,000
 
$
1,067,000
 
 
Amortization expense for the three months ended March 31, 2017 and 2016 was $26,000 and $43,000, respectively. Amortization expense for the six months ended March 31, 2017 and 2016 was $52,000 and $86,000, respectively.
 
Estimated amortization expense for each of the next five fiscal years and thereafter is as follows:
 
 
 
2017 (6 months)
 
2018
 
2019
 
2020
 
2021
 
Thereafter
 
Total
 
Acquired Customer Base
 
$
40,000
 
$
80,000
 
$
84,000
 
$
-
 
$
-
 
$
-
 
$
204,000
 
Know How
 
 
17,000
 
 
34,000
 
 
34,000
 
 
34,000
 
 
34,000
 
 
60,000
 
 
213,000
 
Patents
 
 
4,000
 
 
9,000
 
 
9,000
 
 
9,000
 
 
9,000
 
 
80,000
 
 
120,000
 
 
 
$
61,000
 
$
123,000
 
$
127,000
 
$
43,000
 
$
43,000
 
$
140,000
 
$
537,000
 
 
As of March 31, 2017, Xcede had $259,000 in patents that have not been granted, therefore, the amortization related to these patents is not included in the five-year amortization table above.
 
The Company continually assesses whether events or changes in circumstances have occurred that may warrant revision of the estimated useful lives of its long-lived assets or whether the remaining balances of those assets should be evaluated for possible impairment. There were no changes in the carrying value of the long-lived assets, aside from current additions and foreign exchange rate fluctuations, during the six months ended March 31, 2017.